Shuman Yang1, Susan M Pinney2, Palash Mallick1, Shuk-Mei Ho3, Bruce Bracken4, Tianying Wu5. 1. Department of Environmental Health, Division of Epidemiology and Biostatistics, University of Cincinnati Medical Center, Cincinnati, OH. 2. Department of Environmental Health, Division of Epidemiology and Biostatistics, University of Cincinnati Medical Center, Cincinnati, OH; Cincinnati Cancer Center, Cincinnati, OH. 3. Department of Environmental Health, Division of Environmental Genetics and Molecular and Center for Environmental Genetics, University of Cincinnati Medical Center, Cincinnati, OH; Cincinnati Cancer Center, Cincinnati, OH. 4. Department of Surgery, University of Cincinnati Medical Center, Cincinnati, OH. 5. Department of Environmental Health, Division of Epidemiology and Biostatistics, University of Cincinnati Medical Center, Cincinnati, OH; Cincinnati Cancer Center, Cincinnati, OH. Electronic address: tianying.wu@uc.edu.
Abstract
OBJECTIVE: Biomarkers of oxidative stress and advanced glycation end products (AGE) have been linked to the development of prostate cancer, but evidence from human studies is scarce or controversial. METHODS: We conducted a prospective nested case-control study among 48 men (24 prostate cancer cases and 24 controls) aged 48 to 76 years at baseline. The participants of our study were a part of the Fernald Community Cohort. Prostate cancer cases and controls were matched individually on age (± 3 years) with a 1:1 ratio. Biomarkers included urine F2-isoprostanes (markers of lipid oxidation), plasma fluorescent oxidation products (markers of global oxidation), and carboxymethyllysine (CML) (a major end-stage AGE). RESULTS: At baseline, cases had similar age, body mass index, proportion of family history of prostate cancer, history of benign prostatic hyperplasia, history of hypertension, history of diabetes, number of smokers, and plasma glucose levels compared with controls. Levels of plasma CML were significantly higher in cases than in controls (182 vs. 152 μg/mL, P < .05). In the conditional logistic regression model, an increase in CML equivalent to 1 standard deviation was associated with an increased risk of incident prostate cancer (relative risk, 1.79; 95% confidence interval, 1.00-3.21) and accounted for approximately 8% variance of prostate cancer liability. Urine F2-isoprostanes and plasma fluorescent oxidation products were not associated with prostate cancer incidence. CONCLUSIONS: Higher levels of plasma CML were associated with increased risk of prostate cancer. This suggests a potential new pathway for prostate cancer prediction and treatment.
OBJECTIVE: Biomarkers of oxidative stress and advanced glycation end products (AGE) have been linked to the development of prostate cancer, but evidence from human studies is scarce or controversial. METHODS: We conducted a prospective nested case-control study among 48 men (24 prostate cancer cases and 24 controls) aged 48 to 76 years at baseline. The participants of our study were a part of the Fernald Community Cohort. Prostate cancer cases and controls were matched individually on age (± 3 years) with a 1:1 ratio. Biomarkers included urine F2-isoprostanes (markers of lipid oxidation), plasma fluorescent oxidation products (markers of global oxidation), and carboxymethyllysine (CML) (a major end-stage AGE). RESULTS: At baseline, cases had similar age, body mass index, proportion of family history of prostate cancer, history of benign prostatic hyperplasia, history of hypertension, history of diabetes, number of smokers, and plasma glucose levels compared with controls. Levels of plasma CML were significantly higher in cases than in controls (182 vs. 152 μg/mL, P < .05). In the conditional logistic regression model, an increase in CML equivalent to 1 standard deviation was associated with an increased risk of incident prostate cancer (relative risk, 1.79; 95% confidence interval, 1.00-3.21) and accounted for approximately 8% variance of prostate cancer liability. Urine F2-isoprostanes and plasma fluorescent oxidation products were not associated with prostate cancer incidence. CONCLUSIONS: Higher levels of plasma CML were associated with increased risk of prostate cancer. This suggests a potential new pathway for prostate cancer prediction and treatment.
Authors: A Taguchi; D C Blood; G del Toro; A Canet; D C Lee; W Qu; N Tanji; Y Lu; E Lalla; C Fu; M A Hofmann; T Kislinger; M Ingram; A Lu; H Tanaka; O Hori; S Ogawa; D M Stern; A M Schmidt Journal: Nature Date: 2000-05-18 Impact factor: 49.962
Authors: J D Morrow; W E Zackert; J P Yang; E H Kurhts; D Callewaert; R Dworski; K Kanai; D Taber; K Moore; J A Oates; L J Roberts Journal: Anal Biochem Date: 1999-05-01 Impact factor: 3.365
Authors: Daniel A Barocas; Saundra Motley; Michael S Cookson; Sam S Chang; David F Penson; Qi Dai; Ginger Milne; L Jackson Roberts; Jason Morrow; Raoul S Concepcion; Joseph A Smith; Jay H Fowke Journal: J Urol Date: 2011-04-15 Impact factor: 7.450
Authors: Jasmeet K Gill; Adrian A Franke; J Steven Morris; Robert V Cooney; Lynne R Wilkens; Loic Le Marchand; Marc T Goodman; Brian E Henderson; Laurence N Kolonel Journal: Cancer Causes Control Date: 2009-02-11 Impact factor: 2.506
Authors: Morgan L Zenner; Yves B Helou; Ryan J Deaton; Maria Sverdlov; Heng Wang; Andre Kajdacsy-Balla; Virgilia Macias; Cindy Voisine; Marcus Murray; Sarki A Abdulkadir; Adam B Murphy; Larisa Nonn Journal: Prostate Date: 2021-12-02 Impact factor: 4.104
Authors: Byeongsang Oh; Gemma Figtree; Daniel Costa; Thomas Eade; George Hruby; Stephanie Lim; Aymen Elfiky; Neil Martine; David Rosenthal; Stephen Clarke; Michael Back Journal: Prostate Int Date: 2016-05-24